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Background: Low disease prevalence and lack of uniform reference standards in primary care induce
methodological challenges for investigating the diagnostic accuracy of a test. We present a study design that copes
with these methodological challenges and discuss the methodological implications of our choices, using a quality
assessment tool for diagnostic accuracy studies (QUADAS-2).
Design: The study investigates the diagnostic value of fecal calprotectin for detecting inflammatory bowel disease
in children presenting with chronic gastrointestinal symptoms in primary care. It is a prospective cohort study
including two cohorts of children: one cohort will be recruited in primary care and the other in secondary/tertiary
care. Test results of fecal calprotectin will be compared to one of the two reference standards for inflammatory
bowel disease: endoscopy with histopathological examination of mucosal biopsies or assessment of clinical
symptoms at 1-year follow-up.
Discussion: According to QUADAS-2 the use of two reference standards and the recruitment of patients in two
populations may cause differential verification bias and spectrum bias, respectively. The clinical relevance of this
potential bias and methods to adjust for this are presented. This study illustrates the importance of awareness of
the different kinds of bias that result from choices in the design phase of a diagnostic study in a low prevalence
setting. This approach is exemplary for other diagnostic research in primary care.
Keywords: Primary care, Risk of bias, diagnostic research, Calprotectin, Inflammatory bowel diseaseBackground
In primary care, patients often present with non-specific
symptoms and the incidence of severe illnesses is low.
Differentiating between innocent symptoms and a rare,
but serious organic disease is a diagnostic dilemma for
the primary care physician (PCP). Unnecessary referrals
and diagnostic testing need to be balanced against the
risk of missing a diagnosis and introduction of an un-
acceptable long diagnostic delay. In primary care, both
the PCP and the patient would greatly benefit from sim-
ple, non-invasive and specific screening tests. However,
many of these tests are not validated in primary care.
An example of such a diagnostic dilemma are children
presenting with chronic or recurrent gastrointestinal* Correspondence: m.y.berger@umcg.nl
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reproduction in any medium, provided the orsymptoms. This clinical picture is common, but few chil-
dren will actually have inflammatory bowel disease
(IBD), which includes Crohn’s disease and ulcerative col-
itis. The incidence of non-specific abdominal pain in
Dutch children is 2500/100,000 per year, while the inci-
dence of IBD is 5.2/100,000 per year [1,2]. Clinical
symptoms in children with IBD are often non-specific
and show substantial overlap with functional gastrointes-
tinal disorders [3]. In European secondary and tertiary
care facilities the measurement of calprotectin in stool is
used as an effective triage method for endoscopy, which
is the reference standard for the diagnosis of IBD [4].
Calprotectin is a marker of inflammation that can be
measured by using a simple non-invasive test [5], but
has never been evaluated in children in a primary care
setting [6-8]. The different patient spectrum in primary
care has consequences for the pre-test probability and
test characteristics. Before calprotectin testing can be
recommended to distinguish functional from organical Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Flow chart of the DOK study. The PCP or pediatric
gastroenterologist selects eligible children. At baseline inclusion,
exclusion criteria and red flag symptoms are determined. The
parents and child ≥10 years complete two questionnaires, i.e. a
Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS) and a
symptoms questionnaire, in addition feces (parasites and colon
pathogens) are obtained. Children meeting 1 ≥ red flag symptoms
are evaluated for eligibility for endoscopy by a pediatric gastroente-
rologist. Children without red flag symptoms receive a 1-year
follow-up. The arrows indicate that the PCP can refer a child during
follow-up for endoscopic evaluation and the children who are not
eligible for endoscopy receive a follow-up. After 1 year, information
about diagnosis and clinical symptoms is collected based on the
two above-mentioned questionnaires.
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mation is required on the predictive value of fecal cal-
protectin at the primary care level.
The preferred design to evaluate the diagnostic value
of fecal calprotectin in children with chronic gastrointes-
tinal symptoms would be a cross-sectional study. Such a
design has two methodological challenges. Firstly, the
design of a diagnostic study for rare diseases requires a
large population in order to identify a sufficient number
of children with IBD; the financial and logistic exercise
involved makes such a study infeasible [9]. Secondly, the
preferred reference standard to detect IBD is endoscopy
[10]; but it is unethical to perform this invasive test in
children with a low likelihood of organic gastrointestinal
disease.
Here we present an example of a design that copes
with these methodological challenges. The methodo-
logical implications of applied design choices are exam-
ined using an evidence-based quality assessment tool for
diagnostic accuracy studies (QUADAS-2) [11].
Design
Design and setting
The DOK (Darm Onderzoek bij Kinderen: Bowel Re-
search in Children) study is a prospective cohort study
with a follow-up period of one year, also known as a de-
layed type cross-sectional study [12]. The study consists
of two prospective cohorts. We will recruit a primary
care cohort of children presenting consecutively in pri-
mary care in the northern part of the Netherlands (PCP
cohort). A second cohort consists of children that will
be referred to secondary and tertiary care facilities across
the Netherlands (Hospital cohort). The index test is fecal
calprotectin and the two reference standards for IBD are
endoscopy with histopathological examination of muco-
sal biopsies, or (in children without indication for
endoscopy) assessment of clinical symptoms at 1-year
follow-up (Figure 1) [4,13]. The DOK study was ap-
proved by the Medical Ethics Review Committee of the
University Medical Center Groningen. Written informed
consent will be obtained from the parents and from the
child if aged ≥12 years. Inclusion started in June 2011.
Study population
Children aged 4-18 years presenting with chronic diar-
rhea (≥2 weeks diarrhea or ≥2 episodes of diarrhea in
the past 6 months) or recurrent abdominal pain (≥2 epi-
sodes of abdominal pain in the past 6 months) will be
eligible for participation. Diarrhea was defined as moder-
ately to watery loose stools matching score 5, 6 or 7 of
the Bristol Stool Form Scale [14]. One episode is defined
as 3 days or more.
Exclusion criteria are: a previously established diagno-
sis of chronic organic gastrointestinal disease; a com-plete evaluation in the past 6 months for abdominal
symptoms including endoscopy; chronic use of antibi-
otics, non-steroidal anti-inflammatory drugs (NSAIDs)
or oral corticosteroids (defined as daily use during ≥3
months/year); fecal calprotectin test in the past 6
months, and difficulty in understanding questionnaires.
The number of patients not participating due to the ex-
clusion criteria or refusal are anonymously recorded, in-
cluding the patient characteristics and, if available, the
reason for non-participation.
Measurements
Physical examination
The PCP or pediatric gastroenterologist performs a
structured physical examination and assesses extra-
Table 1 Red flag symptoms of IBD
Red flag symptom Measurement Positive
Growth failure Growth
calculator
Height for age < -1 SDS
Involuntary weight loss History Involuntary decrease in weight
Rectal blood loss History Rectal blood loss with
defecation
Positive family history
of inflammatory bowel
disease
History First-degree relatives
Extra-intestinal
symptoms
Physical
examination
Eyes (episcleritis, scleritis,
uveitis), skin (erythema
nodosum, pyoderma
gangrenosum, psoriasis),
mouth ulcers, finger clubbing,
arthritis
Peri-anal lesions Physical
examination
Skin tags, hemorrhoids,
fissures, fistulas, abscess
Anemia (Hb) Hematology 4-12 years < 7.1 mmol/l,
boy 12-18 years <8.1 mmol/l,
girl 12-18 years <7.4 mmol/l [22]
CRP Chemistry > 10 mg/l [23]
ESR Hematology ≥ 20 mm/h [23,24]
Platelets Hematology > 450 x 109 /l [24]
SDS = standard deviation score; Hb = hemoglobin; CRP = C-reactive protein;
ESR = erythrocyte sedimentation rate.
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the Dutch diagnostic guideline [15]. The participating
PCPs receive training on structured physical examin-
ation of children with symptoms suggestive of IBD.
Questionnaire on pediatric gastrointestinal symptoms
The Dutch version of the Questionnaire on Pediatric
Gastrointestinal Symptoms ROME III (QPGS-RIII) [16]
is completed, by the patient or a parent at baseline and
at 12 months follow-up. The QPGS-RIII consists of two
reports, a parent report for children aged 4-18 years and
a self-report for children aged ≥10 years. The question-
naire has been translated into Dutch. The English ver-
sion of QPGS has good content validity and test-retest
reliability [17,18].
Blood and fecal tests
In the blood sample hemoglobin, erythrocyte sedimenta-
tion rate, C-reactive protein, platelet count and serology
tests for celiac disease (IgA tissue transglutaminase
antibodies) are measured. Feces is tested for colon
pathogens (Salmonella enterica, Campylobacter jejuni,
Shigella spp/EIEC, STEC) and parasites (Giardia lam-
blia, Cryptosporidium spp, Dientamoeba fragilis, Enta-
moebe histolytica) with the real-time multiplex PCRs
[19]. Blood and feces tests are performed at local certi-
fied laboratories. If a child is using NSAIDs, antibiotics
or oral corticosteroids for short-term use (<3 months),
the collection and testing of feces is postponed until the
end of that treatment.
Fecal calprotectin
After baseline assessments the patients send the feces
sample by pre-stamped return envelope to the laboratory
where the samples are stored at -80°C. At the end of the
data collection period the samples are defrosted before
analysis. Fecal calprotectin is measured by means of a
commercially available quantitative enzyme-linked im-
munosorbent assay (ELISA) [20,21]. In accordance with
the manufacturer’s guidelines, values above 50 μg/g feces
are regarded as positive.
Red flag symptoms
In all children red flag symptoms of IBD will be searched
for using a structured evaluation form (Table 1).
Children who fulfill the inclusion criteria and have ≥1
red flag symptoms are referred to a pediatric gastro-
enterologist who will decide whether the child requires
endoscopic examination [15]. This decision will be based
on the medical history, physical examination and blood
testing. Children without red flag symptoms, or those
who are not eligible for endoscopy will be followed for
one year.Endoscopy
Endoscopy is performed under full anaesthesia or deep
sedation by an experienced pediatric gastroenterologist
and entails oesophagogastroduodenoscopy and ileocolono-
scopy. Two biopsies of each intestinal segment are taken.
The histopathological examination will be performed by an
experienced gastrointestinal histopathologist. IBD is classi-
fied according to the Paris classification [10].Follow-up
Follow-up is done using a symptom questionnaire that
was developed for the study in cooperation with
pediatric gastroenterologists and PCPs. This question-
naire will be completed by the parent or child (if aged
≥10 years) at 3, 6, 9 and 12 months follow-up. The PCP
will perform a structured physical examination to assess
red flag symptoms in children with clinical symptoms at
12 months. Those with ≥1 red flag symptoms at 12
months will be referred to a pediatric gastroenterologist
to determine a diagnosis.Blinding
The pediatric gastroenterologists, pathologists, PCPs and
researchers will be blinded to the outcome of the fecal
calprotectin test. The laboratory technician will be
blinded for the clinical characteristics of the child and
the result of endoscopy.
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IBD is confirmed when the endoscopic picture and the
histopathological picture match. Absence of IBD is de-
fined as a negative endoscopic and histopathological
examination, or when there was no indication to per-
form endoscopy at all during the 12 months follow-up.
Besides, all children without red flag symptoms at 12
months follow-up are considered not to have IBD [13].
Sample size
Based on available literature we expect to find a specifi-
city of 93% in the PCP cohort [7,25-27]. To estimate the
specificity and a 95% confidence interval (CI) spanning
5%, we assume a maximum IBD incidence of 5 per 100
children with gastrointestinal complaints and a loss to
follow-up of 10%, we will then need a sample size of 118
children in the PCP cohort. In a worst case scenario with
a specificity of 75%, a sample size of 118 children will
widen the 95% CI to 8% [28].
Sensitivity will be calculated in children with red flag
symptoms (PCP and Hospital cohort). Based on an ex-
pected sensitivity of 95% we need to include 73 children
with IBD in order to estimate the sensitivity and a 95%
CI spanning 5% [7,26,27]. With a prevalence of 80% IBD
and a loss to follow-up of 10% we need to include 100
children with red flag symptoms. The prevalence of IBD
is difficult to estimate; with a prevalence of 20% the
spanning of the 95% CI of the sensitivity will widen to
10% [28].
Statistical analyses
Specificity of fecal calprotectin for IBD in primary care
will be calculated by dividing the number of negative
fecal calprotectin tests by the total number of children
without IBD included in the PCP cohort. Sensitivity will
be calculated by dividing the number of positive fecal
calprotectin tests by the total number of children with
IBD in children with red flag symptoms of both the PCP
and Hospital cohort. The estimates of specificity and
sensitivity will be reported as percentages with 95% CIs.
Discussion
Assessing the risk of bias
To address the risk of bias in our study design and the
applicability of the results we applied the QUADAS-2
checklist [11] that includes four domains: patient selec-
tion, index test, reference standard and flow and timing
(flow of patients through the study and timing of the
index test and reference standard). Each domain was
scored as low or high risk of bias, based on the answers
to the signaling questions. If all answers concerning a
domain are “yes”, the risk of bias can be judged as low.
If any signaling question is answered “no” the risk of
bias can be judged as high. The first two domains werescored as low or high concerns regarding applicability.
Two items were excluded because one item assessed
heterogeneity between studies, which is only applicable
in systematic reviews. The second item asked whether
all patients are included in the analysis, which can only
be assessed after completion of the study. The results of
the QUADAS-2 assessment are shown in Table 2.
Risk of bias
Problems with the reference standard
A perfect reference standard in a diagnostic accuracy
study is said to fulfill three criteria: “1) The reference
standard provides error-free classification of all sub-
jects. 2) The same reference standard is used to verify
all index results. 3) The index test and reference stand-
ard can be performed within a short interval to avoid
changes in target condition status [29].”
Risk of bias in the DOK study is related to the choice
of the reference test, which is not the same for all in-
cluded patients (differential verification bias) [30]. In
addition, follow-up is not considered a reference stand-
ard for IBD in daily practice. This choice may lead to
missed diagnoses and will influence the estimates of
sensitivity and specificity. We chose a differential verifi-
cation design, because it is unethical to perform endos-
copy in children with a low likelihood of organic
gastrointestinal disease. Therefore, children who have a
low IBD risk receive a follow-up of one year, which is
considered to be a suitable period [13]. On the opposite
side, it might be possible that even more children will be
identified because, using a 1-year follow-up, children
with initially mild IBD can be detected when they have
an aggravation of symptoms later in time. These chil-
dren could have been missed when endoscopy was
performed at initial presentation. Children in whom en-
doscopy was not indicated during the 1-year follow-up
(either because they no longer have symptoms or be-
cause their red flag symptoms are not suggestive for
IBD) are considered not to have IBD. The probability
that we will miss a child with IBD is considered to be
extremely low [13]. Adjustment for differential verifica-
tion bias will be made, if possible, using a Bayesian ap-
proach [30,31].
The patient flow of the DOK study could introduce
bias. A delay of one month between stool sample collec-
tion and reference standard is considered to be an ap-
propriate time period. In children of the Hospital cohort
the interval between fecal sampling and endoscopy will
generally be less than one month. For referred children
in the PCP cohort this interval is likely to exceed the
period of one month. To investigate whether the con-
centration of fecal calprotectin accurately measures the
same outcome as endoscopy, feces will be collected
again shortly before endoscopy. In children not referred
Table 2 Quality assessment of the DOK study design (QUADAS-2)
Signaling questions Answer Risk of bias/applicability Planned adjustment
Domain 1: Patient selection
Risk of bias Low risk
Is a consecutive sample of patients enrolled? Yes
Is a case-control design avoided? Yes
Does the study avoid inappropriate exclusions? Yes
Applicability High concern - Magnitude will be evaluated
Are there concerns that the included patients and setting
do not match the topic of our study (patients had symptoms
suggestive of inflammatory bowel disease in primary care)?
Domain 2: Index test
Risk of bias Low Risk
Are the index test results interpreted without knowledge
of the results of the reference standard?
Yes
If a threshold was used, is it pre-specified? Yes
Applicability Low Concern
Are there concerns that the index test, its conduct,
or interpretation differ from the topic of our study
(fecal calprotectin was measured with ELISA)?
Domain 3: Reference standard
Risk of bias High risk
Is the reference standard likely to correctly classify
the target condition?
No - Probably not clinically relevant
- Adjustment in analysis [30,31]
Are the reference standard results interpreted without
knowledge of the results of the index test?
Yes
Domain 4: Flow and timing
Risk of bias High risk
Is there an appropriate interval between index
test and reference standard?
No - Represents care as usual
- Repeated measurement index
test before endoscopy
Do all patients receive a reference standard? Yes
Do all patients receive the same reference standard? No - Adjustment in analysis [30,31]
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tween fecal sampling and reference test will be one year.
During this period the calprotectin concentration may
change and, therefore, the initial test result will no lon-
ger be related to the outcome of endoscopy. This will
underestimate sensitivity and specificity. Here we adopt
a pragmatic approach. We want to establish whether fecal
calprotectin can serve as a screening test in children who
are presenting for the first time to their PCP. A negative
fecal calprotectin value at the start of the study, and a
positive endoscopic result at the end of the study, should
be considered as a false-negative test result.
Applicability of study results
Problems with the patient selection
Test characteristics should be evaluated in a clinically
relevant population [32]. In the DOK study the patientswith symptoms suggestive of IBD will be recruited in
both primary and secondary/tertiary care. Spectrum bias
is to be expected as our patient cohorts will have differ-
ent characteristics [32]. To reduce the risk of spectrum
bias one should ideally only include children who ini-
tially presented at the primary care level. The low prior
probability in this setting makes such a study design in-
feasible with considerable financial and logistic problems
[9]. We decided to use a pragmatic design, based on the
following assumptions: in case of a very low prior prob-
ability of IBD, a PCP wants to avoid unnecessary refer-
rals. The false-positive rate thus needs to be low.
Therefore, we will evaluate specificity of fecal calprotec-
tin in children presenting in primary care. In children
with red flag symptoms, a PCP wants to rule out IBD
and minimize false-negative results. Sensitivity will thus
be evaluated in children referred to secondary or tertiary
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and Hospital cohort).
We assume that this sensitivity is a representative esti-
mate for sensitivity measured in children with red flag
symptoms in primary care. This implies two additional
assumptions: 1) in both cohorts the ratio IBD/non-IBD
in children with red flag symptoms will be comparable
(which we will test); 2) children with red flag symptoms
of both cohorts are comparable (which we will test by
comparing the clinical characteristics). In case the chil-
dren from the Hospital cohort are more severely ill, sen-
sitivity will be overestimated. Heterogeneity can then be
assessed by subgroup analyses of the test performance.Conclusion
Low disease prevalence and lack of uniformity in refer-
ence standard in primary care creates methodological
challenges in primary care level diagnostic accuracy
studies. We presented a pragmatic design in which the
magnitude of potential bias will be assessed and con-
trolled. Awareness of the potential biases and its impli-
cations allows to discuss possible solutions and to
overcome such bias. The validity of diagnostic research
at the primary care level may be considerably improved
with the proposed design.
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